Aptus Capital Advisors’s VanEck Pharmaceutical ETF PPH Stock Holding History

Aptus Capital Advisors’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.9K	Sell	584 -15	-3%	-$1.55K	﹤0.01%	1351
2026 Q1	$62.2K	Buy	599 +38	+7%	+$4.05K	﹤0.01%	1246
2025 Q4	$57.9K	Buy	561 +33	+6%	+$3.21K	﹤0.01%	1273
2025 Q3	$47.7K	Buy	528 +4	+0.8%	+$350	﹤0.01%	1238
2025 Q2	$46.1K	Buy	524 +3	+0.6%	+$260	﹤0.01%	1193
2025 Q1	$47.5K	Sell	521 -10	-2%	-$901	﹤0.01%	1112
2024 Q4	$45.8K	Sell	531 -500	-48%	-$45.2K	﹤0.01%	1118
2024 Q3	$98K	Hold	1,031	–	–	﹤0.01%	852
2024 Q2	$94.3K	Hold	1,031	–	–	﹤0.01%	827
2024 Q1	$93.5K	Buy	+1,031	New	+$90.3K	﹤0.01%	829

Other funds holding PPH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $2.17B AUM 29.66% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.63B AUM 42.75% 1-Year Est. Return

AWC

Adamsbrown Wealth Consultants Wichita, Kansas $530M AUM 23.21% 1-Year Est. Return

Aptus Capital Advisors's PPH Position: Q2 2026 in Review

Aptus Capital Advisors reduced its VanEck Pharmaceutical ETF (PPH) stake by 2.5% in Q2 2026, selling an estimated $1.55K and leaving 584 shares worth $63.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1351.

Aptus Capital Advisors first reported a position in PPH in Q1 2024 and has held it in 10 quarters since. The position peaked at $98K in Q3 2024. 148 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

Aptus Capital Advisors held 584 shares of VanEck Pharmaceutical ETF worth $63.9K as of Q2 2026.
Aptus Capital Advisors sold 15 VanEck Pharmaceutical ETF shares in Q2 2026, an estimated $1.55K.
VanEck Pharmaceutical ETF made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1351 holding.
Aptus Capital Advisors first reported a position in VanEck Pharmaceutical ETF in Q1 2024 and has held it in 10 quarters since.
Aptus Capital Advisors's VanEck Pharmaceutical ETF position peaked at $98K in Q3 2024.
148 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.